Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

NYMX Insider Trading

NYMOX PHARMACEUTICAL CORP | In Vitro & In Vivo Diagnostic Substances

Comprehensive Trading Performance Summary

The investment history of corporate insiders at NYMOX PHARMACEUTICAL CORP provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the In Vitro & In Vivo Diagnostic Substances sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2023-06-26 17:27 2023-04-25 Robinson James George Director, 10% owner BUY $0.46 80,000 $36,800 4,782,065 +1.7%
2023-05-18 23:09 2023-04-25 Robinson James George Director, 10% owner BUY $0.45 40,000 $18,000 4,742,065 +0.9%
2022-05-06 13:00 - Robinson James George Director BUY $1.65 1,151,515 $1,900,000 4,702,065 +32.4%
2021-04-27 18:09 2021-04-21 Robinson James George Director BUY $2.08 40,000 $83,272 3,550,550 +1.1%
2019-07-12 21:07 2019-07-10 Robinson James George Director BUY $1.73 7,000 $12,104 3,510,550 +0.2%
2019-07-10 17:59 2019-07-09 Robinson James George Director BUY $1.63 7,000 $11,400 3,503,550 +0.2%
2019-07-09 20:59 2019-07-05 Robinson James George Director BUY $1.45 9,000 $13,049 3,496,550 +0.3%
2019-07-03 23:18 2019-07-03 Robinson James George Director BUY $1.54 8,000 $12,354 3,487,550 +0.2%
2019-07-02 18:33 2019-07-01 Robinson James George Director BUY $1.37 9,000 $12,305 3,479,550 +0.3%
2019-07-01 22:13 2019-06-28 Robinson James George Director BUY $15.16 10,000 $151,568 3,470,550 +0.3%
2019-06-28 22:53 2019-06-27 Robinson James George Director BUY $1.56 9,000 $14,023 3,460,550 +0.3%
2019-06-27 18:14 2019-06-26 Robinson James George Director BUY $1.71 8,000 $13,680 3,451,550 +0.2%
2019-06-26 18:41 2019-06-25 Robinson James George Director BUY $1.73 9,000 $15,533 3,443,550 +0.3%
2019-06-21 18:55 2019-06-20 Robinson James George Director BUY $1.77 9,000 $15,918 3,434,550 +0.3%
2019-06-20 19:57 2019-06-19 Robinson James George Director BUY $1.69 8,000 $13,529 3,425,550 +0.2%
2019-06-19 21:27 2019-06-18 Robinson James George Director BUY $1.67 9,000 $15,046 3,417,550 +0.3%
2019-06-18 19:19 2019-06-13 Robinson James George Director BUY $1.42 8,000 $11,344 3,408,550 +0.2%
2019-06-12 17:53 2019-06-11 Robinson James George Director BUY $1.46 9,000 $13,149 3,400,550 +0.3%
2019-06-12 17:27 2019-06-10 Robinson James George Director BUY $1.54 8,000 $12,288 3,391,550 +0.2%
2019-06-07 18:42 2019-06-06 Robinson James George Director BUY $1.56 10,000 $15,648 3,383,550 +0.3%
2019-06-06 18:15 2019-06-05 Robinson James George Director BUY $1.55 11,000 $17,093 3,373,550 +0.3%
2019-06-04 23:33 2019-06-03 Robinson James George Director BUY $1.62 9,000 $14,598 3,362,550 +0.3%
2019-06-04 23:28 2019-05-31 Robinson James George Director BUY $1.59 10,000 $15,925 3,353,550 +0.3%
2019-05-31 19:11 2019-05-30 Robinson James George Director BUY $1.76 8,500 $14,968 3,343,550 +0.3%
2019-05-30 17:51 2019-05-28 Robinson James George Director BUY $1.68 9,000 $15,098 3,335,050 +0.3%
2019-05-28 19:19 2019-05-24 Robinson James George Director BUY $1.59 8,000 $12,750 3,326,050 +0.2%
2019-05-28 19:14 2019-05-23 Robinson James George Director BUY $1.55 7,500 $11,657 3,318,050 +0.2%
2019-01-03 21:09 2018-12-21 Danielsen Erik Officer - CFO BUY $1.35 6,000 $8,085 20,900 +40.3%
2019-01-03 21:05 2018-12-19 Danielsen Erik Officer - CFO BUY $1.54 5,000 $7,711 14,900 +50.5%
2018-12-14 23:58 2018-12-13 Robinson James George Director BUY $1.72 5,237 $9,007 3,310,550 +0.2%
2018-12-13 18:43 2018-12-12 Robinson James George Director BUY $1.71 6,000 $10,285 3,305,313 +0.2%
2018-12-12 18:16 2018-12-11 Robinson James George Director BUY $1.67 5,000 $8,359 3,299,313 +0.2%
2018-12-11 18:28 2018-12-10 Robinson James George Director BUY $1.62 7,500 $12,132 3,294,313 +0.2%
2018-12-10 19:41 2018-12-07 Robinson James George Director BUY $1.69 7,000 $11,821 3,286,813 +0.2%
2018-12-07 22:09 2018-12-06 Robinson James George Director BUY $1.74 1,400 $2,436 3,279,813 +0.0%
2018-12-06 22:34 2018-12-04 Robinson James George Director BUY $1.72 7,500 $12,899 3,278,413 +0.2%
2018-12-03 23:43 2018-11-30 Robinson James George Director BUY $1.84 5,000 $9,200 3,270,913 +0.2%
2018-11-30 22:29 2018-11-29 Robinson James George Director BUY $1.81 7,000 $12,660 3,265,913 +0.2%
2018-11-28 23:13 2018-11-27 Robinson James George Director BUY $1.71 8,000 $13,679 3,258,913 +0.2%
2018-11-21 18:56 2018-11-20 Robinson James George Director BUY $1.78 6,000 $10,706 3,250,913 +0.2%
2018-11-21 18:51 2018-11-19 Robinson James George Director BUY $1.74 9,000 $15,675 3,244,913 +0.3%
2018-11-21 18:43 2018-11-16 Robinson James George Director BUY $1.93 6,000 $11,580 3,235,913 +0.2%
2018-11-15 22:50 2018-11-13 Robinson James George Director BUY $2.00 7,000 $13,994 3,229,913 +0.2%
2018-11-13 17:39 2018-11-09 Robinson James George Director BUY $2.09 13,000 $27,225 3,222,913 +0.4%
2018-11-09 17:47 2018-11-07 Robinson James George Director BUY $2.04 363 $740 3,209,913 +0.0%
2018-11-06 19:36 2018-11-02 Robinson James George Director BUY $1.98 7,000 $13,842 3,209,550 +0.2%
2018-11-07 01:33 2018-10-26 Averback Paul Director, Officer, 10% owner - CEO SELL $1.75 100,000 $175,000 23,331,448 -0.4%
2018-11-07 01:26 2018-10-29 Averback Paul Director, Officer, 10% owner - CEO SELL $2.50 1,687,600 $4,219,000 21,643,948 -7.2%
2018-11-07 01:20 2018-10-28 LANHAM RANDALL J Director, Officer - General Counsel BUY $1.72 2,900 $4,988 152,900 +1.9%
2018-11-02 22:46 2018-11-01 Robinson James George Director BUY $1.90 6,000 $11,400 3,202,550 +0.2%
SHOW ENTRIES

How to Interpret $NYMX Trades

Not every insider transaction in NYMOX PHARMACEUTICAL CORP is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $NYMX shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for NYMX

Insider activity data for NYMOX PHARMACEUTICAL CORP is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $NYMX, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.